Hansa Biopharma Announces Positive Idefirix PAES Results Presented at ASN Kidney Week 2026

Hansa Biopharma presented positive results from the European Post-Authorization Efficacy and Safety (PAES) study of Idefirix (imlifidase) at the ASN Kidney Week 2026. The study involved 50 crossmatch-positive deceased-donor kidney transplants in Europe, showing that imlifidase enabled successful transplantation and had a safety profile consistent with prior clinical data. The trial's primary objective was to evaluate graft failure-free survival one year post-transplantation, supporting the clinical utility of imlifidase in highly sensitized patients and aiding the company's move towards full approval in Europe.